Innate Pharma (IPHA) Shares Outstanding (Weighted Average) (2017 - 2025)

Innate Pharma has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $109.1 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 21.78% year-over-year to $109.1 million; the trailing twelve-month figure through Dec 2025 stood at $109.1 million (up 21.78% YoY), and the FY2025 full-year result was $109.1 million, up 21.78% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $109.1 million, up from $282.99 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $109.1 million in Q4 2025, with the low at $21.78 in Q2 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $37.6 million across 5 years, with a median of $2.2 million in 2021.
• The largest YoY upside for Shares Outstanding (Weighted Average) was 527621.42% in 2021 against a maximum downside of 100.0% in 2021.
• Innate Pharma's Shares Outstanding (Weighted Average) stood at $91.0 million in 2021, then retreated by 10.06% to $81.8 million in 2022, then sank by 94.68% to $4.4 million in 2023, then jumped by 1958.81% to $89.6 million in 2024, then climbed by 21.78% to $109.1 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $109.1 million (Q4 2025), $282.99 (Q2 2025), and $89.6 million (Q4 2024), per Business Quant data.